2009
Outcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match
Heilman R, Chakkera H, Mazur M, Petrides S, Moss A, Mekeel K, Mulligan D, Reddy K. Outcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match. Transplantation Proceedings 2009, 41: 303-306. PMID: 19249540, DOI: 10.1016/j.transproceed.2008.08.154.Peer-Reviewed Original ResearchMeSH KeywordsAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntilymphocyte SerumDrug Therapy, CombinationFollow-Up StudiesGraft SurvivalHistocompatibility TestingHumansImmunoglobulins, IntravenousImmunosuppressive AgentsKidney TransplantationPancreas TransplantationRetrospective StudiesSurvival AnalysisTime FactorsTreatment OutcomeConceptsAntibody-mediated rejectionLow-dose intravenous immunoglobulinAcute cellular rejectionIntravenous immunoglobulinStudy groupControl groupAllograft survivalMycophenolate mofetilRisk of AMRSimultaneous pancreas-kidney transplant recipientsPancreas-kidney transplant recipientsSimultaneous kidney-pancreas transplantationDose intravenous immunoglobulinKidney-pancreas transplantationPositive cross matchRabbit antithymocyte globulinActuarial patient survivalKidney allograft survivalKidney transplant recipientsPancreas allograft survivalAcute rejectionAntithymocyte globulinCellular rejectionSPKT recipientsKidney allografts
2008
RISK FACTORS FOR ANTIBODY MEDIATED REJECTION (AMR) IN KIDNEY TRANSPLANT (KTX) RECIPIENTS WITH POSITIVE CDC B-CELL / FLOW CYTOMETRY CROSSMATCH (CXM) TREATED WITH LOE DOSE INTRAVENOUS IMMUNOGLOBULIN (IVIG) AND RATG THERAPY
Moss A, Heilman R, Chakkera H, Mazur M, Petrides S, Wosniak E, Mekeel K, Mulligan D, Reddy K. RISK FACTORS FOR ANTIBODY MEDIATED REJECTION (AMR) IN KIDNEY TRANSPLANT (KTX) RECIPIENTS WITH POSITIVE CDC B-CELL / FLOW CYTOMETRY CROSSMATCH (CXM) TREATED WITH LOE DOSE INTRAVENOUS IMMUNOGLOBULIN (IVIG) AND RATG THERAPY. Transplantation 2008, 86: 591-592. DOI: 10.1097/01.tp.0000330970.94094.7a.Peer-Reviewed Original Research
2006
THE INFLUENCE OF DONOR-SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B-CELL/FLOW CYTOMETRY CROSSMATCH TREATED WITH LOW DOSE INTRAVENOUS IMMUNOGLOBULIN AND ANTI-THYMOCYTE GLOBULIN INDUCTION THERAPY.
Moss A, Heilman R, Mazur M, Chakkera H, Wozniak E, Post D, Mulligan D, Reddy K. THE INFLUENCE OF DONOR-SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B-CELL/FLOW CYTOMETRY CROSSMATCH TREATED WITH LOW DOSE INTRAVENOUS IMMUNOGLOBULIN AND ANTI-THYMOCYTE GLOBULIN INDUCTION THERAPY. Transplantation 2006, 82: 292. DOI: 10.1097/00007890-200607152-00679.Peer-Reviewed Original ResearchAnti-thymocyte globulin induction therapyLow-dose intravenous immunoglobulinDose intravenous immunoglobulinFlow cytometry crossmatchDonor-specific antibodiesKidney transplant recipientsCytometry crossmatchInduction therapyIntravenous immunoglobulinTransplant recipientsCrossmatchTherapyImmunoglobulinRecipientsAntibodies